1. INTRODUCTION
===============

*Acinetobacter baumannii* is a ubiquitous gram-negative *bacillus* that is commonly associated with aquatic environments \[[@R1]\]. Being an opportunistic pathogen; it has been shown to colonize the skin and mucous membranes of the respiratory system of infected individuals \[[@R2]\]. Severe nosocomial infections due to *A. baumannii* are frequently found in the intensive care units (ICUs), which can cause ventilator-associated pneumonia (VAP), septicemia, secondary meningitis, endocarditis, infections of the skin, soft tissues, urinary tract, and those originating from prosthetic devices \[[@R3]-[@R6]\].

Regard to the rapid development of resistance against various antimicrobial agents due to the high ability of natural genetic transformation and the potential for widespread dissemination because of the ability to survive on environmental surfaces, *A. baumannii* has currently surpassed other bacteria as the second most commonly isolated glucose non-fermenter in clinical laboratories after *Pseudomonas aeruginosa* with high mortality rates of 41% \[[@R1]\].

Carbapenems, particularly imipenem, are currently the first choice in the treatment of *A. baumannii*infections \[[@R7]\]. In 1991, the first nosocomial, carbapenem-resistant *A. baumannii* (CR-AB) strain was reported from the USA. Several mechanisms responsible for resistance to carbapenems in CR-AB have been described: production of carbapenemases such as oxacillinases (OXA enzymes), decreased outer-membrane permeability caused by the loss or reduced expression of 29 kDa and 33 kDa porins, and alterations in penicillin-binding proteins and efflux pumps \[[@R8]-[@R10]\].

Serious challenges in the management of critically ill patients with CR-AB infections are exacerbated by widespread multi-, extensively-, and pan-drug resistant (MDR, XDR, and PDR) CR-AB hospital outbreaks in Iran, which present significant health challenges by prolonging hospitalization, treatment failures, and increased mortality \[[@R11],[@R12]\]. Up-to-date surveillance data plus local susceptibility patterns of *A. baumannii* isolates are necessary for appropriate antimicrobial therapy and control of *A. baumannii* hospital outbreaks. Thus, to further address the use of imipenem as an effective antimicrobial agent against clinical *A. baumannii* isolates to control outbreaks and treat patients with *A. baumannii* infections, we investigated the antimicrobial resistance of these microorganisms to imipenem and the frequency of MDR *A. baumannii* strains in Iran using a systematic review and meta-analysis statement according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) \[[@R13]\].

2. METHODS
==========

2.1. Search Strategies
----------------------

A comprehensive search of the literature was performed from Oct 2007--Jul 2015 using Web of Science, PubMed, MEDLINE, ScienceDirect, EMBASE, Scopus, Cochrane Library, and Google Scholar. The search was restricted to original articles published in English and Persian that related to the antimicrobial resistance of *A. baumannii* to imipenem and MDR *A. baumannii*. The key words used were (*Acinetobacter baumannii* OR *A. baumannii* OR *baumannii*) AND (imipenem OR IPM) AND (multi drug resistant OR MDR) AND Iran. With articles published in English, we also reviewed relevant articles in Persian. All published data in Iranian databases, such as Iranmedex (www.iranmedex.com), Scientific Information Database (www.sid.ir), Magiran (www.Magiran.com), Irandoc (www.irandoc.ac.ir) Iranian National Library (www.nlai.ir), Civilica (www.civilica.com), and Pmdr (www.pmdr.ir) in the Persian language were searched with similar strategies and related Persian keywords. We recruited only full text articles, not case reports or conference abstracts. Two independent investigators searched the electronic databases with the identical method. The full texts of articles were reviewed by two independent reviewers to determine if they met eligibility criteria for inclusion. References in the included articles were reviewed to explore additional papers.

2.2. Study Selection
--------------------

All original articles reporting on the antimicrobial resistance of *A. baumannii* to imipenem and the prevalence of MDR *A. baumannii* in Iran were considered. Inclusion and exclusion criteria are listed in Table **[1](#T1){ref-type="table"}**.

2.3. Data Extraction, Synthesis and Analysis
--------------------------------------------

For all studies, the following data were extracted: first author, published time, sample size, study setting, status of resistance to imipenem, and status of MDR (Table **[2](#T2){ref-type="table"}**). Statistical analysis was performed by Comprehensive Meta-Analysis Software Version 2.0 (Biostat, Englewood, NJ). The prevalence was reported with 95% confidence intervals (CIs). After checking the heterogeneity comparison, random effects models were used. To assess potential risk of publication bias, Begg rank correlation and Egger weighted regression methods were used (*P*\<0.05 was considered indicative of a statistically significant publication bias).

3. RESULTS
==========

The result of the search strategies yielded 58 and 21 articles that reported the prevalence of imipenem-resistant *A. baumannii* and MDR *A. baumannii* in Iran, respectively (Fig. **[1](#F1){ref-type="fig"}**). In a secondary screening by implementation of inclusion and exclusion criteria, and based on a title, abstract and full-text evaluation, 51 and 15 articles describing the resistance of *A. baumannii* to imipenem and MDR *A. baumannii* in Iran, respectively were selected for analysis and are presented in Table **[2](#T2){ref-type="table"}**. Most of the studies were performed in central Iran (Tehran)(n=35) compared with the west (n=8), the east (n=0), north (n=4), and south (n=5).

Fig. (**[2](#F2){ref-type="fig"}**) shows the forest plot from the meta-analysis of antimicrobial resistance of *A. baumannii*to imipenem, which the prevalence of it was 54.8% (95% CI, 53.0--56.5). As shown in Fig. (**[3](#F3){ref-type="fig"}**), based on the funnel plot of meta-analysis, some evidence for publication bias was observed. The estimated ranks of correlation coefficients of Begg and Egger were 0.631 and 0.508, respectively. As presented in Table **[2](#T2){ref-type="table"}**, the prevalence of MDR *A. baumannii*was 74.2% (95% CI, 61.3--83.9). The forest plot for the analysis of MDR in the study population is shown in Fig. (**[4](#F4){ref-type="fig"}**). As shown in Fig. (**[5](#F5){ref-type="fig"}**), the funnel plot shows some evidence of publication bias (*P*=0.06 for Begg rank correlation analysis; *P*=0.02 for Egger weighted regression analysis).

4. DISCUSSION
=============

In the recent years, *A. baumannii* infection has become a critical challenge to healthcare systems and has contributed to increased morbidity and mortality among patients in Iran. Control of *A. baumannii*infections is always difficult because of *A. baumannii* resistance to several antimicrobial agents, including imipenem, which remains as the drug of choice, even though frequency of CR-AB isolates are reported to be on the rise worldwide\[[@R7]\]. Widespread outbreaks of carbapenem-resistant MDR, XDR, and PDR *A. baumannii* infections have further limited effective choices for the treatment of *A. baumannii* infections. Studies such as case reports, case series, and small comparative observations on the synergistic effect against MDR *A. baumannii* have been conducted with the use of imipenem in combination with lipopeptides, glycylcyclines, aminoglycosides, aztreonam, rifampicin, ampicillin, and sulbactam \[[@R65]-[@R68]\]. The combinations of imipenem with rifampicin, tigecycline and colistin are recommended as the best therapeutic approach for treatment of nosocomial infections of *A. baumannii* because they are efficacious and show a low toxicity \[[@R69]\].

According to this meta-analysis, 55% of *A. baumannii* isolates were resistant to imipenem, and 74% had a MDR phenotype. The resistance rates of *A. baumannii* to imipenem obtained in this study were higher than those reported in previous studies in Kuwait (42%) \[[@R70]\]. In Iran, the rate of *A. baumannii* resistance to imipenem is considerably lower than the rates found in the neighboring countries, including Pakistan (100%), Turkey (98%), United Arab Emirates (76%), and Saudi Arabia (63%) \[[@R71]-[@R74]\]. According to the last study on antimicrobial resistance of *A. baumannii* isolates, the resistance to imipenem in Turkey increased from 54% in 2008 to 98% in 2011\[[@R72]\].

In Iran, the frequency of MDR*A. baumannii* isolation increased from 50% in 2001--2007 to 74% in 2010--2015, with a mean prevalence of 71%. Possible causes of this 24% increase are: 1) Cross-border exchange among countries such as Iran, Iraq, and Turkey, which reports the highest number of MDR cases; 2) Overuse and/or un-restricted availability of antimicrobial agents, such as imipenem; 3) Improved surveillance and reporting of MDR cases due to increased awareness of clinical microbiologists and infection control specialists concerning imipenem resistance among MDR *A. baumannii;* 4) Utilization of sensitive methods for MDR identification in diagnostic laboratories; 5) A rise in the number of immuno-suppressed chronically ill patients with prolonged hospitalization; 6) Implementation of insurance reform policies and a sharp rise in the number of hospital beds leading to a broader access of Iranian patient population to modern healthcare; as well as expanded access to services such as procedures involving bronchoscopy, which might lead to an increased rate of inadvertent complication involving *A. baumannii* infections in clinics and hospitals \[[@R75]-[@R77]\]. The incidence rate of MDR strains observed in this study was similar to previously reported rates of 67% from Iraq \[[@R78]\]; and it was also lower than reported rates from neighboring countries, such as Pakistan (100%) \[[@R71]\], Kuwait (85%) \[[@R70]\] and United Arab Emirates (83%) \[[@R73]\].

In with regards to the geographic areas, most of the reports included in our meta-analysis were studies conducted in the Iran's capital (Tehran), which is located in central north of the country, where relatively high rate of resistance to imipenem has been reported. The prevalence rate of resistance to imipenem among *A. baumannii* isolates in Tehran reflects the prevalence rate of these microorganisms in Iranian clinical specimens, because Tehran, as the capital of Iran, has many referral health care centers and patients with MDR*A. baumannii* infections who are referred to Tehran for better management and further follow up. The prevalence of imipenem resistance among*A. baumannii* in the west of the country (*e.g.* Tabriz) was high; which might be explained by the proximity of this area to Turkey, which has reported a high prevalence of imipenem-resistant *A. baumannii*.

Our meta-analysis has some inevitable limitations, which should be considered in interpreting our results. The heterogeneity of data could be due to differences in study design or approaches in data collection. In some studies, it was difficult to reach definitive conclusions due to small sample size and low confounders. Because we searched for studies written in English and Persian, studies written in other languages may have been omitted; and, as with any systematic review, we found possible publication bias that should be considered.

CONCLUSION
==========

Our rank-correlated and weighted-regression meta-analysis indicates that antimicrobial resistance among CR-AB and MDR *A.baumannii* isolates from Iran has risen an alarming 24%; and also reveals a 28% increase in imipenem resistance among *A. baumannii*during the past 8 years. This worrisome trend of resistance implies that imipenem may soon be rendered ineffective in treatment of patients with *A. baumannii* infections in Iran, which may be strongly associated with prior use of carbapenems. Fortunately, imipenem-resistant MDR *A. baumannii* isolates have remained susceptible to colistin, which is viable agent in controlling MDR *A. baumannii* outbreaks, especially in developing countries. Our MDR*A. baumannii* susceptibility profile data highlights the urgent need for a comprehensive Iranian national antimicrobial drug resistance survey program in charge of monitoring*A. baumannii* isolates from various parts of Iran towards a rigorous nationwide effort in controlling MDR *A. baumannii* outbreaks. Our systematic review also contends that successful global control measures against *A. baumannii* necessitates policies and concerted efforts that should incorporate local epidemiological data for *A. baumannii* antimicrobial susceptibility profile from all countries in this region, including Iran.
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###### 

Criteria for inclusion and exclusion of studies.

  --------------------------------------------------------------------------------------------------------------------------------------
  **a. Inclusion criteria**\
  *A. baumannii*is a strain for microbiological assessmentFull text articleDrug-resistance data for imipenemMDR *A. baumannii*

  **b. Exclusion criteria**\
  Review articlesCongress abstractsStudies reported in languages other than English or PersianArticles available only in abstract form
  --------------------------------------------------------------------------------------------------------------------------------------

###### 

Studies included in the present systematic review on antibiotic resistance of *A. baumannii* to imipenem and prevalence of MDR *A. baumannii* in Iran.

  First Author (published time)              City           Sample size   Resistance to imipenem   MDR
  ------------------------------------------ -------------- ------------- ------------------------ -----
  Salimizande *et al.,*\[[@R14]\]            Kurdestan      54            28                       \-
  Salimizand *et al.,*\[[@R15]\]             Kerman         40            13                       \-
  Alavi-Moghadam *et al.,*\[[@R16]\]         Tehran         61            61                       \-
  Ahmadi *et al.,*\[[@R17]\]                 Ahvaz          43            33                       \-
  Sharif *et al.,*\[[@R18]\]                 Tehran         200           171                      165
  Nasrolahei *et al.,*\[[@R19]\]             Tehran, Sari   100           67                       100
  Mohajeri *et al.,*\[[@R20]\]               Kermanshah     52            43                       \-
  Abdi-Ali *et al.,*\[[@R21]\]               Tehran         75            51                       \-
  Fallah *et al.,*\[[@R22]\]                 Tehran         108           99                       \-
  Soltani *et al.,*\[[@R23]\]                Isfahan        9             9                        \-
  Mohajeri *et al.,*\[[@R24]\]               Kermanshah     104           83                       34
  Haeili *et al.,*\[[@R25]\]                 Tehran         136           102                      \-
  Goudarzi *et al.,*\[[@R26]\]               Tehran         221           214                      221
  Azimi *et al.,*\[[@R27]\]                  Tehran         93            80                       \-
  Alaei *et al.,*\[[@R28]\]                  Shiraz         85            43                       22
  Safari *et al.,*\[[@R29]\]                 Hamedan        100           85                       \-
  Sadeh *et al.,*\[[@R30]\]                  Tehran         131           131                      115
  Azimi *et al.,*\[[@R31]\]                  Tehran         7             6                        \-
  Jafari *et al.,*\[[@R32]\]                 Fars           63            26                       61
  Owlia *et al.,*\[[@R33]\]                  Tehran         126           107                      \-
  Peymani *et al.,*\[[@R34]\]                Tabriz         134           74                       109
  Asadollahi *et al.,*\[[@R35]\]             Tehran         23            11                       \-
  Sohrabi *et al.,*\[[@R36]\]                Tabriz         100           62                       \-
  Aminzadeh and Yaghubi,\[[@R37]\]           Tehran         39            16                       \-
  Vafaei *et al.,*\[[@R38]\]                 Tehran         100           76                       70
  Talebi-Taher *et al.,*\[[@R39]\]           Tehran         34            34                       \-
  Karbasizade *et al.,*\[[@R40]\]            Isfahan        50            26                       42
  Japoni *et al.,*\[[@R41]\]                 Shiraz         79            18                       \-
  Mirnejad *et al.,*\[[@R42]\]               Tehran         50            39                       41
  Asadollahi *et al.,*\[[@R43]\]             Tehran         100           49                       \-
  Shahcheraghii *et al.,*\[[@R44]\]          Tehran         203           100                      83
  Jazani *et al.,*\[[@R45]\]                 Tehran         48            7                        \-
  Asadollahi *et al.,*\[[@R46]\]             Tehran         100           39                       \-
  Vahdani *et al.,*\[[@R47]\]                Tehran         101           19                       \-
  Peymani *et al.,*\[[@R48]\]                Tabriz         100           54                       31
  Mohammadtaheri *et al.,*\[[@R49]\]         Tehran         136           126                      \-
  Akbari *et al.,*\[[@R50]\]                 Tehran         100           53                       \-
  Moradi--Tabriz *et al.,*\[[@R51]\]         Tehran         166           45                       \-
  Rahbar *et al.,*\[[@R52]\]                 Tehran         88            1                        \-
  Jazani *et al.,*\[[@R53]\]                 Tehran         48            7                        \-
  Rahbar *et al.,*\[[@R54]\]                 Tehran         88            4                        \-
  Soroush *et al.,*\[[@R55]\]                Tehran         145           73                       59
  Taherikalani *et al.,*\[[@R56]\]           Tehran         80            42                       \-
  Jazani *et al.,*\[[@R57]\]                 Tehran         48            7                        \-
  Shahcheraghi *et al.,*\[[@R58]\]           Tehran         95            65                       \-
  Boroumand *et al.,*\[[@R59]\]              Tehran         191           47                       \-
  Hosseini-Jazani *et al.,*\[[@R60]\]        Tehran         48            7                        \-
  Feizabadi *et al.,*\[[@R61]\]              Tehran         108           55                       \-
  Khalatabadi-Farahani *et al.,*\[[@R62]\]   Kashan         48            10                       32
  Rahbaar *et al.,*\[[@R63]\]                Tehran         65            18                       \-
  Khosroshahi *et al.,*\[[@R64]\]            Qazvin         15            4                        \-
